Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
Bioorg Med Chem Lett. 2019 Jan 15;29(2):155-159. doi: 10.1016/j.bmcl.2018.12.007. Epub 2018 Dec 4.
The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.
瞬时受体电位阳离子通道 5(TRPC5)先前已被证明会影响肾脏中的足细胞存活。因此,TRPC5 的抑制剂是治疗慢性肾病(CKD)的有前途的候选药物。在此,我们报告了一系列 N-杂环-1-苄基-1H-苯并[d]咪唑-2-胺作为选择性 TRPC5 抑制剂的合成和生物学特性。这里报道的工作评估了苯并咪唑骨架和取代基,从而发现了 AC1903,这是一种在多种 CKD 动物模型中都具有活性的 TRPC5 抑制剂。